These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

751 related items for PubMed ID: 29620259

  • 1. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H, Zhang C, Chi H, Meng Z.
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [Abstract] [Full Text] [Related]

  • 2. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.
    Wang H, Zhang C, Ning Z, Xu L, Zhu X, Meng Z.
    Int J Oncol; 2016 Mar; 48(3):1229-41. PubMed ID: 26782953
    [Abstract] [Full Text] [Related]

  • 3. Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins.
    Wang H, Zhang C, Chi H, Meng Z.
    Mol Med Rep; 2018 Jun; 17(6):8101-8110. PubMed ID: 29693132
    [Abstract] [Full Text] [Related]

  • 4. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
    Zhai B, Hu F, Yan H, Zhao D, Jin X, Fang T, Pan S, Sun X, Xu L.
    PLoS One; 2015 Jun; 10(9):e0138485. PubMed ID: 26381511
    [Abstract] [Full Text] [Related]

  • 5. Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.
    Dai N, Ye R, He Q, Guo P, Chen H, Zhang Q.
    Oncol Rep; 2018 Dec; 40(6):3235-3248. PubMed ID: 30272354
    [Abstract] [Full Text] [Related]

  • 6. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 7. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.
    Cancer Lett; 2014 Dec 01; 355(1):96-105. PubMed ID: 25218350
    [Abstract] [Full Text] [Related]

  • 8. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z, Wu J, Wu J, Luo D, Jiang C, Ding Y.
    J Exp Clin Cancer Res; 2016 Sep 30; 35(1):159. PubMed ID: 27716356
    [Abstract] [Full Text] [Related]

  • 9. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M, Fei Z, Zhang G.
    Biomed Pharmacother; 2018 Jan 30; 97():1282-1288. PubMed ID: 29156516
    [Abstract] [Full Text] [Related]

  • 10. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 30; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
    Liu LP, Ho RL, Chen GG, Lai PB.
    Clin Cancer Res; 2012 Oct 15; 18(20):5662-71. PubMed ID: 22929805
    [Abstract] [Full Text] [Related]

  • 12. Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.
    Wang H, Zhang C, Xu L, Zang K, Ning Z, Jiang F, Chi H, Zhu X, Meng Z.
    Oncotarget; 2016 Apr 12; 7(15):20193-208. PubMed ID: 26958938
    [Abstract] [Full Text] [Related]

  • 13. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 14. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
    Zhong J, Xiu P, Dong X, Wang F, Wei H, Wang X, Xu Z, Liu F, Li T, Wang Y, Li J.
    Oncol Rep; 2015 Oct 14; 34(4):2142-50. PubMed ID: 26252057
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W, Zhu S, Cao J, Zhang L, Li W, Liu K, Zhong J, Shang C, Chen Y.
    Oncol Res; 2017 Nov 02; 25(9):1543-1553. PubMed ID: 28276313
    [Abstract] [Full Text] [Related]

  • 16. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J, Liu Y, Meng L, Ji B, Yang D.
    Int J Med Sci; 2017 Nov 02; 14(6):523-529. PubMed ID: 28638267
    [Abstract] [Full Text] [Related]

  • 17. Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
    Ling S, Song L, Fan N, Feng T, Liu L, Yang X, Wang M, Li Y, Tian Y, Zhao F, Liu Y, Huang Q, Hou Z, Xu F, Shi L, Li Y.
    Int J Oncol; 2017 Jan 02; 50(1):297-309. PubMed ID: 27959383
    [Abstract] [Full Text] [Related]

  • 18. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
    Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM.
    J Hepatol; 2009 Oct 02; 51(4):725-33. PubMed ID: 19665249
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N.
    Int J Cancer; 2012 Aug 01; 131(3):548-57. PubMed ID: 21858812
    [Abstract] [Full Text] [Related]

  • 20. Effect of PI3K/AKT/mTOR Signaling Pathway on Regulating and Controlling the Anti-Invasion and Metastasis of Hepatoma Cells by Bufalin.
    Sheng X, Zhu P, Zhao Y, Zhang J, Li H, Zhao H, Qin J.
    Recent Pat Anticancer Drug Discov; 2021 Aug 01; 16(1):54-65. PubMed ID: 33530915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.